Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181516 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics
A Phase 2 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT03181516: Completed Phase 2 study, sponsored by Georgetown University.
NCT03181516 is a Phase 2 study that has completed, run by Georgetown University. The registered enrollment target is 255 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03181516, a Phase 2 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. One of the most common indications for probiotic treatment is the prevention of antibiotic-associated diarrhea (AAD). Unfortunately, many probiotic products used for AAD are not supported by rigorous independent research, and often results in non-evidence-based usage. The overarching objective is to move research forward for the most well-studied Bifidobacterium strain. The primary aim is to test the efficacy of high dose, BB-12-supplemented yogurt in preventing AAD, compared to yogurt without BB-12, in children receiving antibiotics. Other aims are to further assess the safety of yogurt supplemented with BB-12, and to carry out longitudinal community structure and gene expression analysis of fecal microbiota to evaluate the impact of high dose BB-12 in a pediatric population receiving antibiotics. The microbiota includes hundreds of species, and its disruption is hypothesized to be an important factor in the development of AAD.
Primary Outcome
Diarrhea is clinically defined as three or more loose stools per day for two consecutive days. This will be a dichotomous (yes or no) outcome of diarrhea.
Interventions
- OTHER Control
- BIOLOGICAL Bifidobacterium animalis subsp. lactis BB-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2017-09-30 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 2 |
What the finished NCT03181516 record still lists
NCT03181516 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher).
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT03181516 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03181516 about?
NCT03181516 is a clinical study titled "Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics". Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. One of the most common indications for probiotic treatment is the prevention of antibiotic-associated diarrhea (AAD). Unfortunately, many probiotic products used for AAD are not suppo...
What is the current status of trial NCT03181516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2017-09-30. Estimated completion is 2023-10-11.
What interventions are being tested in trial NCT03181516?
The interventions under investigation include: Control (OTHER), Bifidobacterium animalis subsp. lactis BB-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03181516?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03181516's enrollment target sits among peer trials
255 218th of 2000 higher than 1,782 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI